STRATEC Biomedical AG 28.07.2014 15:11 Dissemination of a Voting Rights Announcement, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Allianz SE, Munich, Germany, notified us on July 23, 2014 pursuant to section 21 (1) of the German Securities Trading Act (WpHG) as follows: 'We hereby give notice pursuant to section 21 (1) of the German Securities Trading Act (WpHG) in conjunction with section 24 of the German Securities Trading Act (WpHG) that as a result of the merger of Allianz Global Investors France S.A. into Allianz Global Investors Europe GmbH the share of voting rights held by Allianz Global Investors Europe GmbH, Frankfurt am Main, Germany, in STRATEC Biomedical AG, Gewerbestr. 37, 75217 Birkenfeld, Germany, exceeded the 3% and 5% thresholds on July 21, 2014 and amounted to 7.14% (842,323 voting rights out of a total of 11,790,945 voting rights). 5.84% (688,228 voting rights out of a total of 11,790,945 voting rights) were attributed pursuant to section 22 (1) sentence 1 number 6 of the German Securities Trading Act (WpHG). Of these, 600,000 voting rights were attributed by a shareholder whose share of the voting rights amounted to 3% or more pursuant to section 22 (1) sentence 1 number 6 of the German Securities Trading Act (WpHG): Allianz I.A.R.D. S.A.' 28.07.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Internet: www.stratec.com End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-PVR: STRATEC Biomedical AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
| Source: EQS Group AG